Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica

27 July 2021

Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Patrick Johnson, MD

24 June 2021

Aperte le preiscrizioni al Corso SSS in Tecnica dei sistemi – indirizzo chimico farmaceutica

31 May 2021

BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQTM (infigratinib) for Patients with Cholangiocarcinoma

31 May 2021

Lonza raddoppia la produzione di vaccini – Intervista al Presidente di FIT Giorgio Calderari

30 April 2021

Helsinn nomina Mary Lynne Hedley nel Consiglio di Amministrazione

29 April 2021

Helsinn Announces the Launch of Adlumiz® (anamorelin) for the Treatment of Cancer Cachexia in Japan

21 April 2021

Helsinn announces poster presentation at Academy of Managed Care Pharmacy (AMCP)2021 Virtual Meeting evaluating healthcare resource utilization in CINV

13 April 2021

BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology

31 March 2021

“Banche e industria, un binomio vincente nella crisi pandemica”– Tavola rotonda online, ospite il presidente di FIT Giorgio Calderari

25 March 2021